Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct
recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly …

Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

T cells are critical in destroying cancer cells by recognizing antigens presented by MHC
molecules on cancer cells or antigen-presenting cells. Identifying and targeting cancer …

Clinically, cancer drug resistance to chemotherapy, targeted therapy or immunotherapy
remains the main impediment towards curative cancer therapy, which leads directly to …

Interactions of killer cell immunoglobin-like receptors (KIR) with human leukocyte antigens
(HLA) class I regulate effector functions of key cytotoxic cells of innate and adaptive …

Immunotherapy for immune response has ushered in a new era of cancer treatment. In
recent years, new immunotherapeutic agents have been introduced into clinical trials and …

Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …

Simple Summary Cell therapy has transformed oncology and drug development, yet better
model systems are needed to recapitulate the tumor immune microenvironment (TIME) …

The translation of natural killer (NK) cells to the treatment of malignant disease has made
significant progress in the last few decades. With a variety of available sources and …

Abstract Purpose of Review The current review focuses on the preclinical development and
clinical advances of natural killer (NK) cell therapeutics for hematologic malignancies and …